Investigational drug · Phase 2
AP306
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis, End Stage Renal Disease on Dialysis.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "AP306"
First trial start
2026
Jun 1, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AP306", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hyperphosphatemia
- Chronic Kidney Disease Requiring Chronic Dialysis
- End Stage Renal Disease on Dialysis
Approved drugs for the same conditions: Chronic kidney disease · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "AP306" as an intervention, largest first.
- A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With HyperphosphatemiaPivotal-lookingRecruiting
R1 TherapeuticsIndustry
NCT06712654 · 168 participants (planned) · Start Jun 1, 2026 · Primary completion Feb 28, 2027
Drug: AP306 75 mg BID; AP306 125 mg BID and 5 more · For: Hyperphosphatemia; Chronic Kidney Disease Requiring Chronic Dialysis; End Stage Renal Disease on Dialysis
Sites: Huntsville, Alabama; Chula Vista, California; Los Angeles, California · 31 sites in all
Alebund PharmaceuticalsIndustry
NCT05764590 · 55 participants · Start Feb 20, 2023 · Primary completion Aug 25, 2023
Drug: AP-306; Sevelamer Carbonate · For: Chronic Kidney Diseases; Hyperphosphatemia
Sites: Chengdu, China
Newest research
PubMed records naming it or its code names, newest first.
- Novel therapeutic approaches for phosphate regulation.
Alzyood L, Chen W · Curr Opin Nephrol Hypertens 2026
- A Pan-Inhibitor of Phosphate Transporters AP306 in Hemodialysis Patients.
Kowalczyk NS, Sprague SM · Kidney Int Rep 2025
- A Pan-Inhibitor of Phosphate Transporters AP306 in Hemodialysis Patients.
Wang L, Zuo L, Shi M, et al. · Kidney Int Rep 2025
Also in development for Hyperphosphatemia
- AP301Solnatide for reconstitution for forPhase 32 trials
Alebund Pharmaceuticals · Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.